$VKTX News

Last published 2d ago

2d agoVKTXViking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
1w agoPNGAF RHHBY NVO VKTX+1Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 BillionGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic
2w agoVKTXViking Therapeutics Q3 2026 Earnings Call and Webcast - VIKING THERAPEUTICS INCEarnings Call TranscriptsWelcome to the Viking Therapeutics 3rd Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask
2w agoVKTXViking Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2w agoVKTXViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR Newswire-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance ---- SUNRISE Phase 3 Trials for Oral VK2735 Initiated ---- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part
3w agoVKTXViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PR NewswireConference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical
4w agoVKTX VKTKViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityPR NewswireSUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage
1mo agoVKTXViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
1mo agoVKTXViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior NotesPR NewswireViking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
1mo agoVKTXKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ:...
1mo agoVKTXViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior NotesPR NewswireViking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
1mo agoVKTXViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior NotesPR NewswireViking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
1mo agoVKTXViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing RegimensPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
2mo agoVKTXViking Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
3mo agoVKTXViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireViking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
3mo agoVKTXViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
3mo agoVKTXViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
3mo agoVKTXKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ:...
3mo agoVRTX ELDN VKTXA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpPR Newswire(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been...
3mo agoVKTXKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ:VKTX) breached their
3mo agoHYFT ABSI ABCL VKTX+1As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22PR NewswireEquity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical...
4mo agoVKTXViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy AdultsPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
5mo agoVKTXViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical OfficerPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
5mo agoVKTXViking Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
6mo agoABBV ALT MRK SURNF+1Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing
6mo agoVKTXViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
6mo agoVKTXViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
6mo agoVKTXViking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireViking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
6mo agoAVAI LGVN LLY NVO+1The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialGlobeNewswireIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX),
6mo agoVKTXViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
6mo ago.DJI .SPX BA UAL+6Ceasefire extension, Best Buy's new CEO, Amazon's GLP-1 push and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
6mo agoHIMS AMGN VKTX SEPN+3Amazon launches GLP-1 weight loss program, promising 'fast, convenient' accessCNBCThrough Amazon Pharmacy, patients will be able to access medications including Novo Nordisk's Wegovy as well as newer oral GLP-1 options.
7mo agoVKTXViking Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
7mo agoVKTXViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735PR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
8mo agoVKTXViking Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
9mo agoAMRX PBH VKTX PODDAccessible Health Platforms Gain Scale Across $6T Health and Wellness MarketPR NewswireEquity-Insider.com News Commentary – The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual consumer...
9mo agoVKTXViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdatePR NewswireViking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
9mo agoVKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
10mo agoVKTXViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
10mo agoVKTXViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in ObesityPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
10mo agoVKTXViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial OfficerPR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
10mo agoVKTXViking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
10mo agoNVO ELDN VKTX TNDMThe End of Shots? 5 Biotech Stocks Rethinking DiabetesPR NewswireUSA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease...
11mo agoLLY ROG-CH AZN-GB AMGN+3Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, LillyCNBCGrowing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.
11mo agoVKTXViking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
11mo agoVKTXViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735PR NewswireViking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
1y agoVKTXViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
1y agoVKTXViking Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
1y agoVKTXViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025PR NewswireViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
1y agoVKTXViking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireViking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...